Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | CASP1 | P29466 | 3/20 | 0.60 |
| ▸ | CASP7 | P55210 | 3/20 | 0.60 |
| ▸ | HBB | P68871 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.60 |
| ▸ | TOP2A | P11388 | 1/20 | 0.60 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.60 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21841851 | 0.87 | TOP1 (0.58) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL24684669 | 0.87 | TOP1 (0.69) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL21298744 | 0.87 | TOP1 (0.69) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL16307457 | 0.80 | TOP1 (0.67) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL22259156 | 0.80 | TOP1 (0.69) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL12308325 | 0.80 | TOP1 (0.78) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL19346804 | 0.80 | TOP1 (0.64) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27250339 | 0.79 | TOP1 (0.65) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL17775404 | 0.78 | TOP1 (0.52) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL23101918 | 0.77 | TOP1 (0.69) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160143900-A1 | CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION | OYAGEN, INC. (US) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160143900-A1 | CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION | REV1, APOBEC3A, TOP2A | TOP1 11/4885MEN1 2811/4885KMT2A 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.